We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Radcal IBA  Group

Download Mobile App




Ultrasound Contrast Agent Deemed Safe During Stress Echocardiogram

By MedImaging staff writers
Posted on 14 Jul 2008
Recent research has demonstrated that the use of ultrasound contrast agents during stress echocardiograms is safe.

These results, revealed by investigators from the Methodist DeBakey Heart & Vascular Center (Houston, TX, USA) at the 19th annual scientific sessions of the American Society of Echocardiography, held in June 2008, in Toronto, Ontario, Canada, come just months after the U.S. Food and Drug Administration (FDA) mandated a black box warning on the labels of contrast agents used for cardiovascular ultrasound.

The risk of major adverse effects is no different in patients that received contrast during their stress echocardiogram than in those who did not receive contrast, according to research findings. This was evident even though contrast was more frequently used in patients with a higher cardiac risk profile.

"Contrast-enhanced stress echocardiography is a safe option to attain important diagnostic information for patients who need more testing than cardiac ultrasound alone,” said Dr. Kamran Shaikh, postdoctoral echocardiography fellow at the Methodist DeBakey Heart & Vascular Center. "Our research found no link between its use and adverse events or any reason why it shouldn't be available to cardiologists whose patients would benefit from it.”

Contrast, a liquid that is distinctly visible in imaging studies such as echocardiograms, is injected into the heart to enhance the quality of the image. The study examined 3,121 consecutive patients who underwent stress echocardiograms from 2002 through 2007 at the Methodist Hospital (Dallas, TX, USA).

Researchers assessed demographics, contrast use, hemodynamics, electrocardiography (ECG), and wall motion changes, symptoms, and arrhythmias. Contrast was administered in 1,879 of 3,121 patients (60%). None of the patients receiving an ultrasound contrast agent experienced sustained ventricular tachycardia, ventricular fibrillation, cardiac arrest, or death.


Related Links:
Methodist DeBakey Heart & Vascular Center
Biopsy Software
Affirm® Contrast
Pocket Fetal Doppler
CONTEC10C/CL
X-Ray Illuminator
X-Ray Viewbox Illuminators
Computed Tomography System
Aquilion ONE / INSIGHT Edition

Channels

Nuclear Medicine

view channel
Image: LHSCRI scientist Dr. Glenn Bauman stands in front of the PET scanner (Photo courtesy of LHSCRI)

New Imaging Solution Improves Survival for Patients with Recurring Prostate Cancer

Detecting recurrent prostate cancer remains one of the most difficult challenges in oncology, as standard imaging methods such as bone scans and CT scans often fail to accurately locate small or early-stage tumors.... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.